What diseases are Acrivastine capsules used for?

Avastin capsules are a commonly used drug in clinical medicine. Its main ingredient is avastin, which has significant effects in the treatment of allergic rhinitis and allergic skin diseases. It also has the effect of treating chronic spontaneous urticaria and symptomatic skin scratches. Avastin capsules also have the effect of relieving cholestatic urticaria and itching of eczema. However, any drug has its contraindications and adverse reactions. Patients need to fully understand the basic information of the drug based on their own physical condition, and then choose whether to use Acrivastine capsules to treat the disease. At the same time, they need to seek medical treatment in time to recover health as soon as possible.

1. Ingredients

The main ingredient of this product is Acrivastine

Its chemical name is (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid.

Molecular formula: C22H24N2O2

Molecular weight: 348.44

Characteristics

This product is a capsule, and the contents are white granules or powder.

2. Indications

Allergic rhinitis, allergic skin diseases, chronic spontaneous urticaria, symptomatic skin scratches, cholestatic urticaria, spontaneous post-cold urticaria, eczema itching.

Specification

8mg.

3. Usage and Dosage

oral. Adults and children over 12 years old: Take one tablet (8 mg) three times a day.

4. Adverse Reactions

Allergic reactions (ranging from rash to rare anaphylaxis) may occur; drowsiness is rare.

5. Taboo

This product is contraindicated in patients with known hypersensitivity to acrivastine and triprolidine. Because acrivastine is mainly cleared by the kidneys, and acrivastine has not been studied in patients with renal failure, this product should not be used in such patients.

6. Notes

Do not engage in work that requires high alertness while drinking alcohol or taking other central nervous system depressant drugs. Not suitable for children under 12 years old, pregnant women, or breastfeeding women.

7. Use of the drug by pregnant and lactating women

It is not known whether this product is excreted into breast milk. There are currently no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the therapeutic benefit outweighs the potential hazard to the fetus.

8. Use of medication in children

There is no data on the use of this product in children under 12 years old.

9. Medication for the Elderly

There are no specific studies of this product in elderly patients. Until further data are available, this product should not be used in elderly patients.

10. Drug Interactions

Taking it simultaneously with alcohol and other central nervous system depressant drugs may affect concentration and, in severe cases, may cause damage to the central nervous system.

Overdose

There is no experience of overdose with this drug. Appropriate supportive treatment, including gastric lavage, should be used when necessary.

11. Pharmacology and Toxicology

Pharmacodynamics

Acrivastine is a potent competitive histamine H1 receptor antagonist with no obvious anticholine effect and low penetration into the central nervous system. It can relieve the symptoms caused by histamine by completely or partially blocking the release of histamine.

Toxicology studies

Genotoxicity:

No mutagenicity was observed in the consolidation and L5178y/tk+/- lymphocyte assays of Salmonella Ames. In in vitro cytogenetic studies of human lymphocytes, acrivastine did not induce chromosomal abnormalities. In rats, a single oral dose of 1000 mg/kg (5900 mg/m2, 249 times the recommended daily dose for humans) of acrivastine did not reveal normal chromosomal abnormalities in in vivo cytogenetic studies.

Reproductive toxicity:

When rats were given acrivastine alone at a dose of 200 mg/kg/day (1180 mg/m2/day, 50 times the recommended daily dose for humans), it had no effect on the fertility of either male or female rats.

Pregnancy: Teratogenic effects:

Rats and rabbits were given 1000 and 400 mg/kg/day of acrivastine (5900 and 4720 mg/m2/day, 249 and 200 times the recommended daily dose for humans), respectively, without any teratogenic effects. In perinatal and postnatal studies in rats, when acrivastine was administered alone at a dose of 500 mg/kg/day (2950 mg/m2/day, 124 times the recommended daily dose for humans), the mortality rates of maternal and neonatal rats were related to the dose level.

Carcinogenicity:

Rats were given oral acrivastine at a dose of 40 mg/kg/day (236 mg/m2/day, 10 times the recommended daily dose for humans) for 20 to 22 months, and mice were given a dose of 250 mg/kg/day (750 mg/m2/day, 32 times the recommended daily dose for humans) for 20 to 24 months, and no potential carcinogenic effects were observed.

Pharmacokinetics

Acrivastine is well absorbed from the intestine. After healthy adult volunteers took 8 mg of acrivastine, the peak plasma concentration (Cmax) of the drug, which occurred about 1.5 hours (Tmax), was approximately 150 ng/ml. The plasma half-life is approximately 1.5 hours. No accumulation of acrivastine was observed in the 6-day multiple-dose study. Renal excretion is the major route of elimination of acrivastine.